Stockholm Stock Exchange | Mid Cap
Biogaia
+19.02%
Latest
+19.02%
3 months
SEBCarnegieHandelsbankenHandelsbanken Capital Markets

Price Targets For Biogaia

AnalystPrice TargetDateUpside
SEB110 SEKDec -22
+19.02%
Carnegie110 SEKOct -22
Handelsbanken580 SEKSep -21
Handelsbanken Capital Markets590 SEKMay -21

About The Company

Biogaia AB is a Swedish biotechnology company that develops and sells probiotic products. Biogaia has been developed from research findings on the lactic acid bacterium Limosilactobacillus reuteri and the substance reuterin, which was carried out by Walter Dobrogosz and Sven Lindgren in the 1980s.
Wikipedia